Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female, 18 - 70 Years of age~* Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for Generalized Anxiety Disorder (GAD)~* Minimum score of 20 on the Hamilton Rating Scale for Anxiety (HAM-A)~Exclusion Criteria:~* Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control~* Patients with a history of meeting DSM-IV-TR criteria for:~  * any manic, hypomanic or mixed episode, including bipolar disorder and substance-induced manic, hypomanic, or mixed episode;~ * any depressive episode with psychotic or catatonic features;~ * panic disorder with or without agoraphobia;~ * obsessive-compulsive disorder;~ * Schizophrenia, schizoaffective, or other psychotic disorder;~ * bulimia or anorexia nervosa;~ * presence of borderline personality disorder or antisocial personality disorder;~ * mental retardation, dementia, amnesia, or other cognitive disorders~* Patients who are considered a suicide risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets, oral administration
- Vilazadone (Type: EXPERIMENTAL): Vilazadone tablets, oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).